Lonza Signs Agreement to Acquire US CDMO Network from Merck KGaA, Darmstadt, Germany, and Significantly Expands its US Presence

What happened

Lonza signed a definitive agreement to acquire five US CDMO manufacturing sites from Merck KGaA, Darmstadt, Germany. The deal includes about 1,100 employees and is valued in the low- to mid-triple-digit millions Swiss francs, more than doubling Lonza's US footprint to nine CDMO sites.

Confirmed

Global impact / market context

Lonza gains US clinical and commercial manufacturing capacity for bioconjugation, payload-linkers and viral vectors, which means it can offer more services in one place. The roughly 1,100 transferred employees add skilled labor, while the added sites raise Lonza's fixed costs and spending needs in the US.

Analyst inference

Contract manufacturing demand for biologic medicines is growing, and owning US sites can shorten supply chains for American clients. Buying existing sites instead of building them speeds expansion but requires integration spending. Lonza kept its 2026 outlook and Organic Growth Model, signaling the deal is not expected to disrupt near-term profit plans.

Analyst inference

What to watch

1. Lonza confirmed its 2026 financial outlook and its Organic Growth Model, including mid-term financial ambitions, so investors can compare later results against these stated targets. Confirmed
2. Watch whether Lonza discloses integration costs and the purchase price details, since the stated total enterprise valuation is only a low- to mid-triple-digit millions Swiss francs range. Proposed
3. Watch whether the five acquired sites lift revenue and profit per sale over time, and whether the roughly 1,100 transferred employees and new US capacity are used enough to justify the added costs. Analyst inference

Evidence

• eqs-news.com